To date, the only randomized phase III trial was limited to brain metastases and showed no clinical benefits of local stereotactic radiosurgery.47 However, that trial was underpowered because of a small sample size and was terminated early due to slow recruitment because was approved in 2012 in Korea as the first‐line treatment for patients with EGFR mutations.47 Additionally, more than 84% of the included patients had AD. This evidence concerns the gene EGFR and Alzheimer disease.